Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Current Oncology (Toronto, Ont.)
|
February 24, 2023
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
Brandon S Sheffield, Kiefer Eaton, Bruno Emond, et al.
Advances in Therapy
|
July 13, 2022
Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis
Jashin J Wu, Marie-Hélène Lafeuille, Bruno Emond, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 12, 2026
FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T
Rafael Fonseca, Surbhi Sidana, Kevin C De Braganca, et al.
Blood Neoplasia
|
June 2, 2025
Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation
Nilanjan Ghosh, Ruibin Wang, Zaina P Qureshi, et al.
Journal of Comparative Effectiveness Research
|
June 29, 2026
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy
Murali Janakiram, Sabyasachi Ghosh, Victoria Alegria, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 16, 2022
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, et al.
Future Oncology (London, England)
|
July 21, 2023
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, et al.
Current Medical Research and Opinion
|
August 2, 2023
Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
Xiaoxiao Lu, Bruno Emond, Zaina P Qureshi, et al.
Drugs - Real World Outcomes
|
July 31, 2024
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors
Jessica A Walsh, Iris Lin, Ruizhi Zhao, et al.
Rheumatology and Therapy
|
November 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors
Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Current Oncology (Toronto, Ont.)
|
February 24, 2023
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
Brandon S Sheffield, Kiefer Eaton, Bruno Emond, et al.
Advances in Therapy
|
July 13, 2022
Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis
Jashin J Wu, Marie-Hélène Lafeuille, Bruno Emond, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 12, 2026
FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T
Rafael Fonseca, Surbhi Sidana, Kevin C De Braganca, et al.
Blood Neoplasia
|
June 2, 2025
Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation
Nilanjan Ghosh, Ruibin Wang, Zaina P Qureshi, et al.
Journal of Comparative Effectiveness Research
|
June 29, 2026
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy
Murali Janakiram, Sabyasachi Ghosh, Victoria Alegria, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 16, 2022
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, et al.
Future Oncology (London, England)
|
July 21, 2023
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, et al.
Current Medical Research and Opinion
|
August 2, 2023
Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
Xiaoxiao Lu, Bruno Emond, Zaina P Qureshi, et al.
Drugs - Real World Outcomes
|
July 31, 2024
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors
Jessica A Walsh, Iris Lin, Ruizhi Zhao, et al.
Rheumatology and Therapy
|
November 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors
Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Page
of 8